For healthcare professionals only
Hosting partner:
diabetes on the net

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Pharmacy module 3

Chapter 1
Chapter 2
Chapter 3


Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

 PC-GB-108643 V3 | March 2024

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland 

This website is for healthcare professionals in Great Britain, Northern Ireland and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in Great Britain, Northern Ireland or the Republic of Ireland by clicking below.
I am
I am not
Prescribing information for Great Britain and Northern Ireland
Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].


NICE Technology Appraisal Guidance: Tirzepatide (tirzepatide) for treating type 2 diabetes10

Tirzepatide is recommended for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled only if:

  • triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, and
  • they have a body mass index (BMI) of 35 kg/m2 or more, and specific psychological or other medical problems associated with obesity, or
  • they have a BMI of less than 35 kg/m2, and:
    • insulin therapy would have significant occupational implications, or
    • weight loss would benefit other significant obesity-related complications

 

Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for peoplefrom South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.

See NICE TA924

Prescribing information and adverse event reporting for Mounjaro® (tirzepatide) (external link)

Reference: 10. © NICE 2023 Tirzepatide for treating type 2 diabetes. Available from https://www.nice.org.uk/guidance/TA924. Accessed March 2024. All rights reserved. Subject to Notice of rights.

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
CLOSE

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel